This site is intended for healthcare professionals only

Issue:

Share this article
Share on facebook
Share on twitter
Share on email
Share on print

At a glance factsheet: GLP-1 receptor agonists and diabetic retinopathy

Stephen Bain
An unexpected safety signal emerged from the SUSTAIN 6 cardiovascular outcomes trial of the glucagon-like peptide-1 receptor agonist (GLP-1 RA) semaglutide, whereby increased rates of diabetic retinopathy were observed in trial participants randomised to semaglutide. This finding has, justifiably, led to a great deal of investigation and caution. This At a Glance factsheet outlines the evidence regarding diabetic retinopathy in users of the GLP-1 RA class as a whole, and provides recommendations on safe use.

Share this article
Share on facebook
Share on twitter
Share on whatsapp
Share on email
Share on print

Readers are directed to the PDF version of this article.

For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
Free for all UK & Ireland healthcare professionals

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.